

Controversies in thyroid cancer management

Chair: Dagmar Fuhrer and Johannes W Smit

PROGRAM (status 02.07.2014)

08:00 - 08:30	Registration and coffee
08:30 – 08:35	Presidential address and Introduction Dagmar Fuhrer, President of ETA-CRN (Germany)
08:35 – 10:15	Up-to-date diagnosis of differentiated thyroid cancer Molecular diagnostics in FNA: gene expression or mutation based approach?: 08:35 – 09:05 For gene expression (AFIRMA) classifier: Richard T. Kloos (USA) 09:05 – 09:35 For mutation based approach: Markus Eszlinger (Germany) 09:35 – 10:00 Discovering DTC recurrence by conventional vs. highly sensitive Tg assays: L. Giovanella (Switzerland) 10:00 – 10:15 Discussion
10:15 – 11:30	What is the present role of molecular pathology? Should BRAF positive cancers be managed differently?: 10:15 – 10:45 For: Michael Mingzhao Xing (USA) 10:45 – 11:15 Against: Laura Fugazzola (Italy) 11:15 – 11:30 Discussion
11:30 – 11:45	COFFEE BREAK
11:45 – 13:00	Cardiovascular events and TSH suppression 11:45 – 12:15 Do the patients with thyroid cancer die from cardiovascular events, not disease? Esther Klein Hesselink, Thera Links (The Netherlands) 12:15 – 12:45 What are the present indications for L-thyroxine TSH-suppressive therapy in thyroid cancer patients? Johannes W Smit (The Netherlands) 12:45 – 13:00 Discussion
13:00 – 13:30	Approach to complex issues in Thyroid Cancer 13:00 – 13:15 EUROCRINE Project – the European Register of Rare Endocrine Tumors: Marcin Barczynski (Poland) 13:15 – 13:30 Other initiatives: Dagmar Fuhrer
13:30 – 13:45	General comments and any other business
